|
Patent landscape, scope, and claims: |
United States Patent 11,174,481 Scope, Claims, and Patent Landscape for RNAi Agent Compounds (R=RNAi; Y=O/S; Y′=O″/S″/NH″)
Executive summary: U.S. Patent 11,174,481 is directed to a defined chemical compound class (and pharmaceutically acceptable salts) where a key substituent R is an RNAi agent, and heteroatom positions Y and Y′ are restricted to specific oxygen/sulfur/nitrogen variants (Y=O or S; Y′=O″, S″, or NH″). The claim set shown is narrow in structure-defining elements, but it can still cover multiple members of an RNAi-containing scaffold depending on how the “RNAi agent” term is construed in the specification and dependent claim structure limitations. The practical landscape risk and licensing/infringement exposure will hinge on (1) the exact structural variables defined by the “compound having a structure selected from the group consisting of:” clause, (2) whether “RNAi agent” is limited to a specific RNA modality/chemistry in the written description, and (3) whether later-art compounds change Y/Y′ positions or modify the RNAi moiety in a way that avoids the claim-defined structural selection.
What does US Patent 11,174,481 claim for RNAi compounds with Y=O/S and Y′=O″/S″/NH″?
Direct answer: The independent claim covers a compound (or its salt) whose structure is selected from an enumerated set “consisting of” (not provided in your excerpt), with the following explicit mandatory features:
- R = an RNAi agent
- Y = O or S
- Y′ = O″ or S″ or NH″
Dependent claims narrow further:
- Claim 2: Y = S
- Claim 3: Y = O
- Claim 4: Y′ = O″
Claim-by-claim scope mapping (based on the excerpt)
| Claim |
Limitation additions vs. Claim 1 |
Scope consequence |
| 1 |
Compound structure selected from a specified “group consisting of” set; R=RNAi agent; Y=O or S; Y′=O″/S″/NH″ |
Sets the core covered scaffold family and RNAi coupling variable |
| 2 |
Y = S |
Carves out one heteroatom variant, narrowing to the sulfur version(s) |
| 3 |
Y = O |
Carves out one heteroatom variant, narrowing to the oxygen version(s) |
| 4 |
Y′ = O″ |
Narrows Y′ to an oxygen-defined variant |
Key limitation that governs enforceable scope
The most legally consequential element you did not include is the exact set of structures referenced after:
“wherein R is an RNAi agent, Y is O or S, and Y′ is 0″, S″, or NH″.”
and, earlier, the phrase:
“wherein a structure [is] selected from the group consisting of: [structures not shown].”
Without the enumerated structure set, the full claim boundary (which structural embodiments are inside or outside) cannot be fully reconstructed from the excerpt.
How broad is the “structure selected from the group consisting of” language in US 11,174,481?
Direct answer: “Selected from the group consisting of” is typically interpreted as closed-set claiming for the enumerated structures included in the specification/claims. If the claim lists specific structural formulas, substitution outside the listed structures can fall outside the literal claim scope, even if the substitution is chemically similar.
Practical claim construction impacts
- Closed selection set: If the “group consisting of” list is explicit in the full claim text, the claim usually covers only those listed variants.
- Parameter flexibility depends on what the list actually covers: If the enumerated structures differ only by variables like Y and Y′ and/or RNAi attachment, then the claim may effectively cover a small finite family. If the list includes multiple variants with different RNAi chemistries or linkers, the scope expands correspondingly.
- RNAi agent definition is pivotal: “R is an RNAi agent” is a functional label that can be construed narrowly or broadly depending on how the patent defines “RNAi agent” in the specification (e.g., siRNA, shRNA, duplex siRNA, siRNA with specific backbone modifications, conjugated RNAi ligands).
Where claim scope can be narrowed by interpretation
- If “RNAi agent” is defined in the specification to mean a specific RNA modality (e.g., duplex siRNA with particular chemical modifications), competitors using other RNAi constructs can argue non-equivalence to the claimed RNAi definition.
- If the claim’s enumerated structures include specific linker chemistries connecting the RNAi agent to the rest of the compound, replacing the linker can be outside literal scope even if Y and Y′ remain O/S variants.
What does US 11,174,481 cover for RNAi agent chemistry, and what claim variables are fixed?
Direct answer: Based on the excerpt, the fixed structural variables are:
- R: an RNAi agent
- Y: O or S
- Y′: O″, S″, or NH″
Everything else depends on the unseen structure group in Claim 1.
Likely fixed elements (high-level)
For claims of this type, the specification typically fixes:
- attachment point of the RNAi moiety (where R attaches)
- linker or heteroatom platform that contains Y and Y′
- stereochemistry and ring positions (if the structures are enumerated)
Where freedom for design-around often exists
- changing the RNAi agent chemistry so it no longer fits the specification’s “RNAi agent” definition
- selecting a heteroatom state outside Y=O/S or Y′=O″/S″/NH″
- substituting at positions not controlled by the enumerated structures
Which embodiments fall under Y=S vs Y=O in US 11,174,481, and how does that affect infringement analysis?
Direct answer: The patent explicitly provides dependent narrowing to two heteroatom configurations:
- Claim 2 covers embodiments where Y=S
- Claim 3 covers embodiments where Y=O
Infringement logic
- Literal infringement for the dependent claims requires the accused compound to satisfy all limitations of Claim 1 plus the specific value of Y.
- Even if an accused compound includes the same RNAi agent definition and matches the Y′ variant(s), a mismatch on Y (O vs S) can defeat the dependent claim but may still potentially infringe Claim 1 if Y is O or S and the compound’s overall structure is within the “selected from the group consisting of” set.
Competitive significance
- Competitors frequently tune heteroatoms in linker/platform chemistry to optimize stability, conjugation, and release kinetics. If Y is a defined position within the scaffold, that becomes a common design-around axis.
When does Y′=O″ matter in US 11,174,481, and does it narrow to a specific product profile?
Direct answer: Claim 4 isolates embodiments where Y′=O″.
Practical effect
- If the “Y′” position is part of a functional group controlling hydrolysis, solubility, or metabolic stability, then Y′=O″ may map to a specific chemical profile in marketed candidates.
- If later products use Y′=S″ or Y′=NH″ alternatives, they may attempt to avoid Claim 4 while still potentially falling under Claim 1 (because Claim 1 includes all listed Y′ values).
How strong is the patent estate around US 11,174,481 for RNAi-linked compounds?
Direct answer: With only Claim text excerpted, strength is governed less by claim count and more by:
- whether the patent’s “structure selected from the group consisting of” list is small (stronger exclusionary power for those exact structures) or large (broader coverage)
- whether “RNAi agent” is construed broadly
- whether there are other family members with overlapping or broader chemical coverage (not determinable from the excerpt alone)
What to look for in the full patent file history (enforcement-relevant)
For RNAi conjugate compounds, the strongest “estate” often comes from multiple patents covering:
- core scaffold structures (chemical formula claims)
- linker chemistry (process or intermediate claims)
- specific RNAi modality-conjugate combinations (examples and narrower claims)
- salts/solid forms (polymorph, hydrate, co-crystal claims)
None of that can be enumerated without the actual patent family members and written description content.
What patent landscape challenges exist from generic or alternative RNAi conjugate developers to US 11,174,481?
Direct answer: For RNAi-containing conjugates, “generic” is typically a misfit because these products are often regulated as new drugs with complex chemistry. The real competitive threat is structural design-around and therapeutic equivalence rather than a direct “generic” identical copy.
Common competitive design-around approaches
- Replace the heteroatom position values outside Y=O/S and Y′=O″/S″/NH″
- Use a different RNAi agent format that falls outside the specification’s “RNAi agent” definition
- Modify linker attachments so the compound is not among the enumerated “selected from the group consisting of” structures
- Use alternative salts to avoid literal infringement of a claim limited to a particular salt set (though Claim 1 here explicitly covers “pharmaceutically acceptable salt thereof,” which reduces that lever)
What is the likely FDA and exclusivity posture relevant to US 11,174,481?
Direct answer: No FDA Orange Book or exclusivity posture can be mapped to this patent from the excerpt alone because the patent’s drug association, NDA/BLA number, and listed active ingredient are not provided.
How does US 11,174,481 compare with typical RNAi conjugate patent claim strategies in the US?
Direct answer: The claim strategy here is a compound formula-style scaffold claim with:
- a functional/defined moiety insertion (R is an RNAi agent)
- explicit limited heteroatom state options (Y and Y′)
That is consistent with US practices where chemical patents aim to fence specific chemical space while leaving some variability in the RNAi agent or other substituted elements, depending on how broadly the specification supports the term.
Typical outcomes in litigation/invalidation (pattern-based)
- If prior art discloses the scaffold but not the RNAi-agent embodiment, novelty can rest on the RNAi insertion.
- If prior art discloses RNAi conjugates broadly, inventive step may fail unless the patent ties RNAi type or placement to a distinct structural configuration.
These outcomes depend on the actual prior art record and the patent’s specification support for “RNAi agent.”
Key Takeaways
- U.S. Patent 11,174,481 Claim 1 covers an RNAi-linked compound family where R is an RNAi agent, and the scaffold includes Y=O or S and Y′=O″/S″/NH″, limited to a closed set of enumerated structures (“selected from the group consisting of”).
- Claims 2–4 carve out narrower heteroatom embodiments: Y=S, Y=O, and Y′=O″.
- The enforceable boundary is dominated by the unseen enumerated structural set in Claim 1 and by the patent’s defined meaning of “RNAi agent.”
- Competitive risk is most acute for products whose scaffold is among the enumerated variants and whose RNAi moiety construction fits the patent’s described RNAi definition.
- A full landscape assessment (family size, expiration, other claim sets, and FDA linkages) cannot be completed from the excerpted claim text alone.
FAQs
- Does “pharmaceutically acceptable salt thereof” in US 11,174,481 broaden infringement coverage beyond the base compound?
- If an accused compound uses Y′=S″ instead of Y′=O″, can it still infringe Claim 1 even if it avoids Claim 4?
- How do “R is an RNAi agent” clauses usually get construed when the specification defines RNAi modality and chemistry?
- What design-around typically targets “selected from the group consisting of” limitations in compound claims?
- How do dependent heteroatom claims (Y=S, Y=O) interact with the independent claim when assessing literal infringement?
References (APA)
- United States Patent No. 11,174,481, claims as provided in the prompt.
More… ↓
⤷ Start Trial
|
